BEDFORD, Mass., April 23, 2018 – Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer. Mr. Brumm, an accomplished CFO with extensive financial and operational experience, will report directly to chief executive officer and chair, Michael Bonney.
“We are excited to welcome Josh to our executive team at Kaleido,” said Mr. Bonney. “He has a proven track record of guiding life science companies through significant growth, including leading financing transactions, business development, strategic planning and product and medical device launches. Josh will play an integral role in our efforts to continue to advance Kaleido’s pipeline and innovative, capital-efficient discovery and development model. He also shares our team’s drive to pioneer new approaches that can transform patients’ lives.”
Mr. Brumm has more than a decade of operations, finance and investment banking experience in the life science industry. Most recently, Mr. Brumm served as CFO and chief operating officer at Versartis, Inc., where he oversaw the company’s financial strategy, helped negotiate the company’s first product partnership and led the successful completion of a $145 million initial public offering. Prior to that, he was executive vice president of finance and principal financial officer at Pharmacyclics, Inc., and CFO at ZELTIQ Aesthetics, Inc. In both of these roles, he was responsible for the strategic planning, development and leadership of the corporate finance organization. Mr. Brumm also was director of finance at Proteolix, Inc., helping in the sale of the company to Onyx Pharmaceuticals. Over the course of his career in corporate finance, Mr. Brumm has raised more than $700 million in equity financings, completed two initial public offerings and was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million in 2014. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. He holds a B.A. in Business Administration from the University of Notre Dame.
“I’m honored to join a company that is committed to transforming the way we treat disease and manage human health by exploring the power of the microbiome,” said Mr. Brumm. “I look forward to working with an extraordinary team to realize Kaleido’s exciting growth prospects and to translate innovative microbiome science into new advances for patients.”
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome’s natural roles in promoting health. For more information, please visit: https://kaleido.com.
Amy Reilly, 617-890-5721